^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
GB241 (rituximab biosimilar)
i
Other names: GB241
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Nanjing Yoko Biomedical, Walvax
Drug class:
CD20 inhibitor
Related drugs:
3ms
A Study Comparing the Efficacy and Safety of G-CHOP Versus R-CHOP in Untreated Diffuse Large B-cell Lymphoma Patients (clinicaltrials.gov)
P3, N=360, Recruiting, Nanjing Yoko Biomedical Co., Ltd. | Unknown status --> Recruiting | Trial completion date: Oct 2021 --> Dec 2025
Enrollment open • Trial completion date
|
CD20 (Membrane Spanning 4-Domains A1)
|
CD20 positive
|
Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • GB241 (rituximab biosimilar)
3years
A Study Comparing GB241 And Rituximab in Patients With B-cell Non-Hodgkin's Lymphoma (clinicaltrials.gov)
P1, N=85, Completed, Nanjing Yoko Biomedical Co., Ltd. | Recruiting --> Completed
Clinical • Trial completion
|
CD20 (Membrane Spanning 4-Domains A1) • CD19 (CD19 Molecule)
|
CD20 expression
|
Rituxan (rituximab) • GB241 (rituximab biosimilar)
over3years
Clinical • Enrollment change • PD(L)-1 Biomarker
|
CD20 (Membrane Spanning 4-Domains A1)
|
Keytruda (pembrolizumab) • Rituxan (rituximab) • Gazyva (obinutuzumab) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • Novex (rituximab biosimilar)
over3years
Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma (clinicaltrials.gov)
P2; N=45; Not yet recruiting; Sponsor:Academic and Community Cancer Research United
New P2 trial • Clinical
|
CD34 (CD34 molecule)
|
clonoSEQ
|
Rituxan (rituximab) • cytarabine • bortezomib • doxorubicin hydrochloride • cyclophosphamide • Calquence (acalabrutinib) • prednisone • daunorubicin • Rituxan Hycela (rituximab/hyaluronidase) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Novex (rituximab biosimilar) • cyclophosphamide intravenous
over3years
Rituximab, Pembrolizumab, and Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma (clinicaltrials.gov)
Trial completion date: Feb 2021 --> Feb 2023 | Trial primary completion date: Feb 2021 --> Feb 2023
Clinical • Trial completion date • Trial primary completion date • PD(L)-1 Biomarker
|
CD20 (Membrane Spanning 4-Domains A1)
|
Keytruda (pembrolizumab) • Rituxan (rituximab) • Gazyva (obinutuzumab) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • Novex (rituximab biosimilar)
over4years
A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma (clinicaltrials.gov)
P2; Not yet recruiting --> Recruiting
Enrollment open • Clinical
|
CCND1 (Cyclin D1) • CD34 (CD34 molecule)
|
CCND1 expression
|
clonoSEQ
|
Rituxan (rituximab) • cytarabine • Calquence (acalabrutinib) • bendamustine • Belrapzo (bendamustine RTD) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Novex (rituximab biosimilar)
over4years
A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma (clinicaltrials.gov)
P2; N=369; Not yet recruiting; Sponsor:ECOG-ACRIN Cancer Research Group
New P2 trial • Clinical
|
CCND1 (Cyclin D1) • CD34 (CD34 molecule)
|
CCND1 expression
|
clonoSEQ
|
Rituxan (rituximab) • cytarabine • Calquence (acalabrutinib) • bendamustine • Belrapzo (bendamustine RTD) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Novex (rituximab biosimilar)
Share via
